Research
Hormonal
Off-label use of generic medications (e.g., metformin, SGLT2 inhibitors) or compounded GLP-1 agonists carries risks of unknown efficacy, safety issues, and potential adverse events compared to FDA-approved anti-obesity medications.
Avoid compounded or off-label obesity medications. They are not regulated for safety or efficacy and may contain unapproved ingredients. Talk to your doctor about FDA-approved options, even if they are expensive, as they are the only ones proven safe and effective.
ModerateRefutesMEDIUM confidence
Off-label treatments for patients with obesity can have unexpected interactions with other medications, worse health outcomes, and unknown long-term side effects.
Why this rating
Based on FDA warnings and lack of clinical trial data for compounded versions.
Source
Setting Expectations When Prescribing Medication for the Treatment of Patients With Obesity
Angela Fitch · Mayo Clinic Proceedings Innovations Quality & Outcomes · 2025
DOI 10.1016/j.mayocpiqo.2025.100621
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Anti-obesity medications (AOMs) combined with lifestyle modifications produce greater and more sustained weight loss (5-23%) compared to lifestyle changes alone, with specific agents like semaglutide and tirzepatide showing superior efficacy.Good
- Achieving 5-10% weight loss through any method (including medication) is associated with significant improvements in obesity-related comorbidities, including type 2 diabetes prevention, cardiovascular risk reduction, and NAFLD resolution.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →